Role of the Metabolic Syndrome in Risk Assessment for Coronary Heart Disease
- Priya Kohli, Commentary by, MD;
- Philip Greenland, MD
- Author Affiliations: Northwestern Memorial Hospital (Dr Kohli) and Department of Preventive Medicine, Northwestern University Feinberg School of Medicine (Dr Greenland), Chicago, Ill. Dr Greenland is the Editor, Archives of Internal Medicine.
- Corresponding Author: Philip Greenland, MD, Archives of Internal Medicine, Northwestern University Feinberg School of Medicine, 680 N Lake Shore Dr, Suite 1102, Chicago, IL 60611 (p-greenland{at}northwestern.edu).
Since this article does not have an abstract, we have provided the first 150 words of the full text.
ARCHIVES OF INTERNAL MEDICINE
Metabolic Syndrome vs Framingham Risk Score for Prediction of Coronary Heart Disease, Stroke, and Type 2 Diabetes Mellitus
S. Goya Wannamethee, PhD; A. Gerald Shaper, FRCP; Lucy Lennon, MSc; Richard W. Morris, PhD
Background: We sought to compare metabolic syndrome (MetS) with the Framingham Risk Score (FRS) as predictors of coronary heart disease
(CHD), stroke, and type 2 diabetes mellitus (DM2) in middle-aged men.
Methods: A prospective study of 5128 men aged 40 to 59 years with no history of cardiovascular disease (CVD) (CHD or stroke) or DM2
drawn from general practices in 24 British towns and observed for 20 years. Metabolic syndrome was defined as the presence
of 3 or more metabolic abnormalities based on modified National Cholesterol Education Program criteria.
Results: Men with MetS at baseline (26%) showed significantly higher relative risk (RR) than men without MetS of developing CHD (RR,
1.64; 95% confidence …
